MORE►
Rett syndrome
[Source image: istockphoto]
Taysha Gene Therapies Raises $150M for Its Rare Disease Drug Pipeline
by Lance Murray | Aug 16, 2023
Led by new investor RA Capital Management, the new funding is expected to extend Taysha's cash runway into the third quarter of 2025, and aid in its development of a gene therapy treatment targeting Rett Syndrome, a neurological disorder that occurs primarily in girls.
![R.A. Session II, president, CEO, and founder of Taysha Gene Therapies [Background image: Olena Yepifanova via iStock]](https://s24806.pcdn.co/wp-content/uploads/2020/04/TayshaGene-Session-970-1-360x203.jpg)
by Kevin Cummings |
Oct 25, 2022
The investment by Tokyo-based Astellas Pharma gives it a 15% stake in Taysha and positions it to potentially purchase the company, according to the Dallas Morning News. The Dallas-based biotech firm's pipeline includes the "first-and-only" gene therapy in clinical development for Rett syndrome and a Phase 1/2 development of a treatment for an inherited nervous system disorder that's awaiting regulatory feedback.
“We believe this investment not only further validates the potential of our technology platform, but also reinforces the therapeutic and market opportunity of our two lead clinical assets,” Founder and CEO R.A. Sessions II says.
“We believe this investment not only further validates the potential of our technology platform, but also reinforces the therapeutic and market opportunity of our two lead clinical assets,” Founder and CEO R.A. Sessions II says.
MORE►
